Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. METHODS: Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo. The primary end point was overall survival. Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life. RESULTS: The median duration of survival was 20.3 months in the group given IFL plus bevacizumab, as compared with 15.6 months in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001). The median duration of progression-free survival was 10.6 months in the group given IFL plus bevacizumab, as compared with 6.2 months in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 percent and 34.8 percent (P=0.004). The median duration of the response was 10.4 months in the group given IFL plus bevacizumab, as compared with 7.1 months in the group given IFL plus placebo (hazard ratio for progression, 0.62; P=0.001). Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 percent vs. 2.3 percent) but was easily managed. CONCLUSIONS: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Necrosis promotes the expression of VEGFa, as dying tumor cells release signals that stimulate the growth of new blood vessels33,53.”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [33]
In the citing paper
“Subsequently, as several phase III trials had demonstrated that FOLFOX and XELOX are comparable in the context of metastatic colorectal cancer33–35”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [33]
In the citing paper
“It has been reported that increased SFK expression occurs in approximately 80% of CRC specimens when compared to the normal adjacent colonic epithelium (Hurwitz et al., 2004).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Hurwitz et al., 2004
In the citing paper
“The median overall survival in the IFL and bevacizumab arm was 20.3 months versus 15.6 months in the IFL alone arm.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [46]
In the citing paper
“The anti-VEGF antibody bevacizumab (BEV) is used in combination with chemotherapy (FOLFOX or FOLFIRI) for the treatment of mCRC with activating mutations in the RAS/RAF/MAPK pathway [121].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [121]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Self-citationIrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationYang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Self-citation
Research works printed but not linked: 4
- Presta LG, 1997, Cancer Res, 57, 4593
- Nissen NN, 1998, Am J Pathol, 152, 1445
- Hurwitz H, 2002, Prog Proc Am Soc Clin Oncol, 21, 82
- Benson AB, 2003, Prog Proc Am Soc Clin Oncol, 22, 243
Cited by
Items 101–200 of 1,082
Autocrine VEGF Signaling Is Required for Vascular Homeostasis
Lee, S., Chen, T. T., Barber, C. L., Jordan, M. C., Murdock, J., Desai, S., Ferrara, N., Nagy, A., Roos, K. P., & Iruela-Arispe, M. L. (2007) · Cell · doi:10.1016/j.cell.2007.06.054 · Cited by 1,046
Self-citationLessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Self-citationVerwaal, V. J., Bruin, S., Boot, H., van Slooten, G., & van Tinteren, H. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9966-2 · Cited by 1,033
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032
Rees, M., Tekkis, P. P., Welsh, F. K. S., O'Rourke, T., & John, T. G. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31815aa2c2 · Cited by 1,026
Strategies for Safer Liver Surgery and Partial Liver Transplantation
Clavien, P.-A., Petrowsky, H., DeOliveira, M. L., & Graf, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmra065156 · Cited by 1,022
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Kamba, T., & McDonald, D. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603813 · Cited by 990
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Self-citationZalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968
Powe, C. E., Levine, R. J., & Karumanchi, S. A. (2011) · Circulation · doi:10.1161/circulationaha.109.853127 · Cited by 967
Innocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964
Folprecht, G., Gruenberger, T., Bechstein, W. O., Raab, H.-R., Lordick, F., Hartmann, J. T., Lang, H., Frilling, A., Stoehlmacher, J., Weitz, J., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70330-4 · Cited by 963
Langley, R. R., & Fidler, I. J. (2011) · International Journal of Cancer · doi:10.1002/ijc.26031 · Cited by 958
Takahashi, H., & Shibuya, M. (2005) · Clinical Science · doi:10.1042/cs20040370 · Cited by 953
Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., Kakkar, A., Kuderer, N. M., Levine, M. N., Liebman, H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1283 · Cited by 952
Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausova, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 946
Self-citationScappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H.-P., Miller, K., Kabbinavar, F., Bergsland, E., Ngai, J., Holmgren, E., Wang, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm086 · Cited by 938
Self-citationKabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., Mass, R., Perrou, B., Nelson, B., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 929
Self-citationVenook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7105 · Cited by 898
“dence indicated that cetuximab activity was unrelated to tumor expression of EGFR.(8) Bevacizumab, a humanized”
BackgroundRosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-14 · Cited by 904
Pathophysiological consequences of VEGF-induced vascular permeability
Weis, S. M., & Cheresh, D. A. (2005) · Nature · doi:10.1038/nature03987 · Cited by 909
Soft-Tissue Sarcomas in Adults
Clark, M. A., Fisher, C., Judson, I., & Thomas, J. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041866 · Cited by 907
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Mirnezami, A., Mirnezami, R., Chandrakumaran, K., Sasapu, K., Sagar, P., & Finan, P. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e3182128929 · Cited by 875
Cassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9898 · Cited by 862
Simmonds, P. C., Primrose, J. N., Colquitt, J. L., Garden, O. J., Poston, G. J., & Rees, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603033 · Cited by 858
Liu, Z., Liu, L., Weng, S., Guo, C., Dang, Q., Xu, H., Wang, L., Lu, T., Zhang, Y., Sun, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28421-6 · Cited by 843
Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Self-citationFuchs, C. S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery, M., Schulz, J., Richards, D., Soufi-Mahjoubi, R., Wang, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3357 · Cited by 851
Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F., Mulcahy, M. F., O'Reilly, E., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 845
Self-citationCardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Antiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 828
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers
Okugawa, Y., Grady, W. M., & Goel, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.011 · Cited by 782
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818
“81) 3 [105]”
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 809
Epithelial-mesenchymal transition in cancer development and its clinical significance
Iwatsuki, M., Mimori, K., Yokobori, T., Ishi, H., Beppu, T., Nakamori, S., Baba, H., & Mori, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2009.01419.x · Cited by 780
Tournigand, C., Cervantes, A., Figer, A., Lledo, G., Flesch, M., Buyse, M., Mineur, L., Carola, E., Etienne, P.-L., Rivera, F., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0106 · Cited by 805
Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
Avery, R. L., Pearlman, J., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., Giust, M. J., Wendel, R., & Patel, A. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.064 · Cited by 799
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304121.57857.38 · Cited by 801
Shibuya, M. (2013) · Journal of Biochemistry · doi:10.1093/jb/mvs136 · Cited by 792
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 779
Colucci, G., Gebbia, V., Paoletti, G., Giuliani, F., Caruso, M., Gebbia, N., Cartenì, G., Agostara, B., Pezzella, G., Manzione, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.113 · Cited by 779
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O'Brien, S. M., Davis, R. B., Gowen, L. C., et al. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 775
Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model
Ma, L., Reinhardt, F., Pan, E., Soutschek, J., Bhat, B., Marcusson, E. G., Teruya-Feldstein, J., Bell, G. W., & Weinberg, R. A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1618 · Cited by 772
Nalluri, S. R., Chu, D., Keresztes, R., Zhu, X., & Wu, S. (2008) · JAMA · doi:10.1001/jama.2008.656 · Cited by 771
Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., Douglas, J., Burger, R. A., Armstrong, D., Wenham, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0782 · Cited by 759
Transport of drugs from blood vessels to tumour tissue
Dewhirst, M. W., & Secomb, T. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.93 · Cited by 749
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis
Eyler, C. E., & Rich, J. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1829 · Cited by 737
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
Lohela, M., Bry, M., Tammela, T., & Alitalo, K. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.012 · Cited by 738
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734
“In CRC, the novel therapies that are currently used target the vascular endothelial growth factor and epidermal growth factor (EGF) signaling pathways (Kabbinavar et al, 2003; Hurwitz et al, 2004; Saltz et al, 2004).”
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Molecular basis for sunitinib efficacy and future clinical development
Faivre, S., Demetri, G., Sargent, W., & Raymond, E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2380 · Cited by 721
Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
Hernandez–Gea, V., Toffanin, S., Friedman, S. L., & Llovet, J. M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.002 · Cited by 722
Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J. O., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 714
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654
Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Natural products as leads to anticancer drugs
Gordaliza, M. (2007) · Clinical and Translational Oncology · doi:10.1007/s12094-007-0138-9 · Cited by 701
Epidermal Growth Factor Receptor Targeting in Cancer
MENDELSOHN, J., & BASELGA, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
Grothey, A., Sugrue, M. M., Purdie, D. M., Dong, W., Sargent, D., Hedrick, E., & Kozloff, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3212 · Cited by 688
Hurwitz, H. I., Fehrenbacher, L., Hainsworth, J. D., Heim, W., Berlin, J., Holmgren, E., Hambleton, J., Novotny, W. F., & Kabbinavar, F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.017 · Cited by 688
Self-citationKabbinavar, F. F., Hambleton, J., Mass, R. D., Hurwitz, H. I., Bergsland, E., & Sarkar, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.232 · Cited by 686
Self-citationEngstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y.-J., Choti, M. A., Cooper, H. S., Covey, A., Dilawari, R. A., Early, D. S., Enzinger, P. C., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0056 · Cited by 683
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682
“The comparison of chemotherapy and bevacizumab versus chemotherapy alone was outside the scope of this systematic review; however, the Expert Panel acknowledges that previous studies have established this combination as the standard initial treatment for mCRC.(32,33) Doublet-chemotherapy continues to be the preferred…”
BackgroundCancer associated fibroblasts (CAFs) in tumor microenvironment
Xing, F. (2010) · Frontiers in Bioscience · doi:10.2741/3613 · Cited by 682
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
Ruers, T., Van Coevorden, F., Punt, C. J. A., Pierie, J.-P. E. N., Borel-Rinkes, I., Ledermann, J. A., Poston, G., Bechstein, W., Lentz, M.-A., Mauer, M., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx015 · Cited by 682
Kennedy, A., Nag, S., Salem, R., Murthy, R., McEwan, A. J., Nutting, C., Benson, A., Espat, J., Bilbao, J. I., Sharma, R. A., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.11.060 · Cited by 676
Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
Hallmarks of alternative splicing in cancer
Oltean, S., & Bates, D. O. (2014) · Oncogene · doi:10.1038/onc.2013.533 · Cited by 664
MICHELS, S., ROSENFELD, P., PULIAFITO, C., MARCUS, E., & VENKATRAMAN, A. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.02.007 · Cited by 664
Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action
FOLKMAN, J. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.015 · Cited by 658
Mechanisms of Drug Resistance in Cancer Chemotherapy
Luqmani, Y. A. (2005) · Medical Principles and Practice · doi:10.1159/000086183 · Cited by 651
Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J.-L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0238 · Cited by 650
Rothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646
Self-citationCunningham, D., Lang, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., Jonker, D., Osborne, S., Andre, N., Waterkamp, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70154-2 · Cited by 643
Hu-Lowe, D. D., Zou, H. Y., Grazzini, M. L., Hallin, M. E., Wickman, G. R., Amundson, K., Chen, J. H., Rewolinski, D. A., Yamazaki, S., Wu, E. Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0652 · Cited by 635
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq020 · Cited by 638
“The clinical benefit of bevacizumab is well established across a range of tumour types, including colorectal cancer [5, 6], metastatic breast [7] and renal cancers [8].”
BackgroundSchwartzberg, L. S., Rivera, F., Karthaus, M., Fasola, G., Canon, J.-L., Hecht, J. R., Yu, H., Oliner, K. S., & Go, W. Y. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2473 · Cited by 635
Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea
Benson, A. B., Ajani, J. A., Catalano, R. B., Engelking, C., Kornblau, S. M., Martenson, J. A., McCallum, R., Mitchell, E. P., O'Dorisio, T. M., Vokes, E. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.132 · Cited by 631
Zhu, X., Wu, S., Dahut, W. L., & Parikh, C. R. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.11.039 · Cited by 632
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
Folprecht, G., Grothey, A., Alberts, S., Raab, H.-R., & Köhne, C.-H. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi246 · Cited by 632
Koopman, M., Antonini, N. F., Douma, J., Wals, J., Honkoop, A. H., Erdkamp, F. L., de Jong, R. S., Rodenburg, C. J., Vreugdenhil, G., Loosveld, O. J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61086-1 · Cited by 630
Follicular B helper T cells in antibody responses and autoimmunity
Vinuesa, C. G., Tangye, S. G., Moser, B., & Mackay, C. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1714 · Cited by 624
Gerber, H.-P., & Ferrara, N. (2005) · Cancer Research · doi:10.1158/0008-5472.671.65.3 · Cited by 626
Self-citationHochster, H. S., Hart, L. L., Ramanathan, R. K., Childs, B. H., Hainsworth, J. D., Cohn, A. L., Wong, L., Fehrenbacher, L., Abubakr, Y., Saif, M. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4138 · Cited by 613
Self-citationDifferential Roles of Vascular Endothelial Growth Factor Receptor-1 and Receptor-2 in Angiogenesis
Shibuya, M. (2006) · BMB Reports · doi:10.5483/bmbrep.2006.39.5.469 · Cited by 623
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
Kulke, M. H., Lenz, H.-J., Meropol, N. J., Posey, J., Ryan, D. P., Picus, J., Bergsland, E., Stuart, K., Tye, L., Huang, X., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9020 · Cited by 623
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Dougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
Metadata
- Authors
- Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., & Kabbinavar, F.
- Affiliations
- Duke University (US)
- Kaiser Permanente (US)
- Genentech (US)
- Sarah Cannon (US)
- Hematology and Oncology Associates of Northeastern Pennsylvania (US)
- Vanderbilt University (US)
- California Pacific Medical Center (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-06-03
- Volume
- 350
- Issue
- 23
- Pages
- 2335-2342
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2157769714
- Cited by
- 10,968
- References
- 14
- Citations by year
- 2026: 127 · 2025: 162 · 2024: 242 · 2023: 276 · 2022: 264 · 2021: 270 · 2020: 289 · 2019: 293 · 2018: 323 · 2017: 422 · 2016: 462 · 2015: 523 · 2014: 608 · 2013: 671 · 2012: 711
- FWCI
- 339.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k23ca085582-06)
- National Cancer Institute (K23 CA085582-04)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- bevacizumab, metastatic colorectal cancer, irinotecan, 5-fluorouracil, leucovorin, anti-VEGF monoclonal antibody, combination chemotherapy, overall survival, progression-free survival, hypertension, first-line therapy
- MeSH terms
- Bevacizumab, Irinotecan, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Quality of Life, Colorectal Neoplasms, Survival Analysis, Disease-Free Survival, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.